- Company
- Profitable lazertinib makes 5-year income for Oscotec
- by An, Kyung-Jin Feb 2, 2021 06:25am
- For last couple of years, Oscotec has generated 57 billion won from licensing out a new drug candidate. The South Korean company earned more than five years of income by selling a profitable new drug candidate to Yuhan Corporation. On Jan. 26, Oscotec announced Yuhan Corporation would pay out USD 22.1 million (approximately 24.8 billion
- Policy
- Samyang Biopharm started to develop generic for Votrient
- by Lee, Tak-Sun Feb 2, 2021 06:25am
- It was found that a domestic pharmaceutical company started developing Votrient’s generic for Novartis' blockbuster kidney cancer treatment. Generic for Votrient is attracting attention in that there are no commercialized items yet. The MFDS approved the bioequivalence test protocol of Samyang Biopharm’s SYO-1987 on the 28th of last
- Company
- COX-2 inhibitors recover and grow 56% in 5 years
- by Kim, Jin-Gu Feb 2, 2021 06:25am
- The prescription volume of cyclooxygenase-2 (COX-2) inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs) seems to be increasing rapidly. A major product Celebrex (celecoxib) had its pricing cut by half after its patent was expired in 2015, but the prescription volume soared by 56 percent in five years until last year. The industry expert
- Policy
- Administration of AZ vaccine to the elderly is appropriate
- by Lee, Tak-Sun Feb 2, 2021 06:25am
- The MFDS’ verification advisory group composed of domestic experts presented an opinion that there was no reason to exclude the administration of AstraZeneca's COVID-19 vaccine to the elderly. In addition, it was evaluated that the inoculation was performed twice at the standard dose, and the inoculation interval was appropriate for 4 to 12
- Company
- MSD Korea reaches collective agreement with union
- by Feb 2, 2021 06:25am
- MSD Korea (CEO Kevin Peters) announced the company reached a collective agreement with the labor union on Jan. 28 before fully splitting off Organon Korea. This marks the first collective agreement settled since the establishment of MSD Korea Labor Union. And the company noted that it was a mutual collaborative outcome of the management
- Policy
- Clinical data for the elderly for the AZ vaccine are lacking
- by Kim, Jung-Ju Feb 1, 2021 11:52pm
- The detailed schedule and plan for vaccination in Korea was announced, and a limited vaccination discussion continues overseas due to the lack of clinical data for AstraZeneca (AZ)'s COVID-19 vaccine, and the results of the review by licensing authorities are drawing attention later. The MFDS will take all these into account and conduct a
- Company
- KRPIA appoints Oh Dong-wook Chairman & new BOD is launched
- by Eo, Yun-Ho Feb 1, 2021 06:16am
- Along with the appointment of a new chairman, there have been significant changes in the KRPIA’s BOD. On the 27th, the KRPIA announced that, after Avi BenShoshan, former CEO of MSD Korea, Oh Dong-wook, CEO of Pfizer Korea, was elected as the 14th chairman and will lead the association from February 2021. The KRPIA plans to newly launch
- Opinion
- [Reporter’s View] The transparency in COVID-19 drug review
- by Lee, Tak-Sun Feb 1, 2021 06:16am
- The public is keeping a close eye on the South Korean Ministry of Food and Drug Safety (MFDS) approving the COVID-19 vaccine and treatment. Especially because the pharmaceuticals and their efficacy have been controversial overseas, the public’s interest is heightened on the result of the health authority’s evaluation. To guarantee an
- Company
- Daewoong & Roche were selected as Best Companies to Work for
- by Eo, Yun-Ho Feb 1, 2021 06:15am
- This year, many healthcare companies were listed as one of the top 100 companies to work for. According to related industries, companies such as Daewoong, Roche Diagnosis, Baxter, and Medtronic were selected as the 'Best Companies to Work for in Korea 2020' hosted by the global HR consulting firm GPTW Institute (Great Place to Work Institu
- Company
- Disappointing result of first 2021 Cancer Committee meeting
- by Eo, Yun-Ho Jan 29, 2021 06:14am
- The National Health Insurance (NHI) reimbursement expansion on the indication targeting ‘all-comer’ and a combined targeted therapy would have to wait for another time. The Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee convened a first meeting of the year yesterday, and they decided the coverage o
